INKT MiNK Therapeutics Inc

$INKT Can you name a single Botech with the risk/reward profile as great as INKT? The TAM here is massive. Think about the years a drug must be in Trials to prove effectiveness for Prostate Cancer or even NSCLC, versus Trials on critically ill patients with ARDS, which will reveal results quickly.

$INKT As a final matter regarding the current Phase 2 ARDS study: • Regulatory Milestones: Management is preparing to meet with the FDA to discuss leveraging these Phase 2 results for sample-size re-estimation and transitioning directly into a seamless Phase 3 study design.

$INKT The initial subjects treated in MiNK Therapeutics' C-1300-02 Phase 2 trial were alive at Day 28 and showed significant clinical recovery, including improved oxygenation, resolution of acute respiratory distress syndrome (ARDS), return to spontaneous breathing, and removal from ventilator and vasopressor support. Clinical Status Details • Survival: 100% alive at the Day 28 primary endpoint. • Respiratory Function: Improved oxygenation and resolution of ARDS. • Support Removal: Liberated from mechanical ventilators and vasopressors. • Infection & Fever: Controlled baseline infections and became afebrile. • Biomarkers: Showed reduced inflammatory markers and tissue/immune recovery signals. • Adverse Events: No major serious adverse events attributed to the therapy.

$INKT Last night, as I sat rolling a couple fingers of Weller 12 year old against my palms, I thought about all the speculative stocks I had purchased over many, many years. My face was reflected in the powered-down computer screen in front of me, and seemed content...but weary. That look I mused, came from years of fighting on the market ropes, through raging seas and weathered hopes. Indeed...I am weary of waiting....wait, wait, wait....patience...and usually I wait some more, but almost always...nothing happens. The stock sits there like a tall ship with no wind...dead in the water. Still, once in a blue moon the wind picks up...the sails unfurl and fill...and the boat begins to gather speed. Hoping for a nice ride on the USS - INKT.

$INKT massive spike potential $DPRO wedged between SMA200 and upper bollinger, strong potential, shorts in danger ⚠️

$INKT mah got goosebumps… big jump premarket still highly manipulated so no one can see it … love this play , I keep buying

$INKT What is the Net Present Value of Agent-797 when the drug hits the market in ‘28? NPV $1,518,243,459 Disc Finance Rate 30% Investment Cost ($25.0M) Profit Streams Yr ‘28 - $856.9M Yr ‘29 - $910.7M Yr ‘30 - $967.9M Yr ‘31 - $1,028.7M Assumption 1. The global ARDS market will be $3.46B in ‘26 and has a CAGR of 6.28%, and of that market 43.85% will suffer from moderate-to-severe hypoxemia Assumption 2. Big Pharma’s Cost-of-Capital for high risk assets is 30% and this will be our Discount Rate Assumption 3. Mink is producing and scaling Agent-797 and will probably incur costs of $25M Assumption 4 I have Agent-797 capturing only 50% of the entire Global ARDS market relating to moderate-to-severe hypoxemia

$INKT $ICU How the hell should I know, you’re the one that’s been here 2 months of Sundays. You tell me. ————————-++++++♾️++++++——————-

$INKT I hope everyone is focused on risk / reward and fundamentals here. ST showing SP up big pre-market today … on a volume of 2 shares. Yeap, someone traded 2 shares, about $25, and moved the reported pre-market SP. Buy this one on future potential, LT outlook, no worries. 2 share trades … too funny.

$INKT the guy from agen inc. Will talk about agent t797 (minks product) … I’m thinking the stocks should correlate in price movement… that being said inkt is behind

$INKT Strange that both INKT & IBRX both had big premarket and early trading volume spikes yesterday Coincidence? Or is the cat out-of-the-bag?

$INKT rn the doubt is whether Lviv can provide good enrollment pace. First 2 pts were recruited over the course of ~1 month. Could they ramp it up and recruit the full n=10 run-in cohort by the end of this month? Then we could have 28 days data around the end of October. I don't think they can reasonably start the randomized portion without a full run-in dataset. I'm looking at that 90 days mortality endpoint with some concerns. Is that endpoint blocking too? That would put randomized portion start in January ;-/

$INKT comparatively to the market… inkt is holding for now relatively speaking. Wait and see this could be bikini bottom

$INKT Sorry, cash moving forward? QTRLy burn rate? ICU investor here. Been through our 1/250 and still believe that will be completely erased in the next 4-5 years. Is this ♾️ sign biotech about to ramble down that path? It looks strong here. TIA.